Safety, Pharmacokinetics and Preliminary Efficacy of IL4-R α Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study

ConclusionsAK120 exhibited an acceptable safety profile in healthy and AD subjects, and showed preliminary efficacy. These findings support the continued investigation of AK120 for treating AD.Clinical Trial RegistrationClinicalTrials.gov identification number: NCT04256174.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research